National Public Radio

Posted by:

FDA recently announced the approval of Probuphine, an implantable form of buprenorphine, for treating opioid dependence. National Public Radio sought the views of Dr. Cidambi, addiction expert and medical director of the Center for Network Therapy, on the medication. Dr. Cidambi laid out the case why the uptake of Probuphine would fall well short of expectations despite its potential to help individuals suffering from opiate withdrawal and opiate cravings.


About the Author:

New Jersey's premier addiction treatment center, offering medically managed detox and rehabilitation treatment programs.
  Related Posts

Add a Comment